Eptacog alfa

Drug Profile

Eptacog alfa

Alternative Names: Activated recombinant human factor VII; Factor VIIa; NiaStase; NN 007; NovoSeven; NovoSeven RT; NovoSeven RT with MixProT; NovoSeven with pre-filled syringe; Novostase; Recombinant factor VIIa; rFVIIa

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ZymoGenetics
  • Developer Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Recombinant proteins
  • Mechanism of Action Factor VIIa stimulants; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Haemorrhage; Haemophilia; Thrombasthenia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Factor-VII-Deficiency; Haemophilia; Thrombasthenia
  • Discontinued Haemorrhage

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jun 2017 Novo Nordisk completes a phase II trial in Thrombasthenia (In children, In adults, In adolescents, In the elderly) in Japan (IV) (NCT01876745)
  • 07 Jul 2014 Registered and launched for Glanzmann's thrombasthenia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top